“Whoa! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia



Curr Oncol Rep (2010) 12:352­354 DOI 10.1007/s11912-010-0122-3 CLINICAL TRIAL REPORT Amit Mahipal & Mark Weiss Published online: 1 September 2010 # Springer Science+Business Media, LLC 2010 Robak T, Dmoszynska A, Solal-Celigny P, et al.: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1756­1765. Rating ·Of importance. Introduction Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the United States [1]. There has been considerable progress in understanding the biology and treatment of CLL in last 20 years. The introduction of purine analogs (pentostatin, fludarabine, and cladribine) dramatically increased the response rates compared to alkylating agents [2, 3]. Combination chemoimmunotherapy has further improved the overall frequency of response to over 80% in treatment-naïve and over 60% in relapsed/ refractory disease, respectively [4­7]. The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has been demonstrated to be one of the most effective regimens in younger patients with CLL in phase 2 trials. Tam et al. [4], reporting on 300 patients, noted an overall response frequency of 95% with 72% achieving complete response (CR) in patients treated with FCR as initial therapy for



Current Oncology ReportsSpringer Journals

Published: Nov 1, 2010

DOI: 10.1007/s11912-010-0122-3

Free Preview of First Page

Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.